| A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults (NCT07717775) | Addpharma Inc. | 2026-08-01 |
| A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B (NCT07730567) | Addpharma Inc. | 2026-07-29 |
| A Study to Evaluate the Safety, Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects (NCT07717749) | Addpharma Inc. | 2026-07-24 |
| A Clinical Trial to Evaluate the Bioequivalence of AD-116A Compared to AD-1161 in Healthy Adult Male Volunteers (NCT07715305) | Addpharma Inc. | 2026-07-01 |
| A Clinical Trial to Evaluate the Bioequivalence of AD-116A and AD-1161 Under Fed Conditions in Healthy Adult Male Volunteers (NCT07722871) | Addpharma Inc. | 2026-07-01 |
| Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee (NCT07550231) | Addpharma Inc. | 2026-06-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C (NCT07590167) | Addpharma Inc. | 2026-06-01 |
| A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults (NCT07618845) | Addpharma Inc. | 2026-05-01 |
| A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults (NCT07521241) | Addpharma Inc. | 2026-05-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232 (NCT07538466) | Addpharma Inc. | 2026-04-01 |
| A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults (NCT07385248) | Addpharma Inc. | 2026-04-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects (NCT07476157) | Addpharma Inc. | 2026-04-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects (NCT07444385) | Addpharma Inc. | 2026-02-26 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers (NCT07495514) | Addpharma Inc. | 2026-02-10 |
| Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 (NCT07312799) | Addpharma Inc. | 2026-01-27 |
| Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' (NCT07385235) | Addpharma Inc. | 2026-01-27 |
| A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers (NCT07103278) | Addpharma Inc. | 2026-01-22 |
| A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A (NCT07152873) | Addpharma Inc. | 2025-12-01 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282 (NCT06858865) | Addpharma Inc. | 2025-07-12 |
| A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B (NCT06884085) | Addpharma Inc. | 2025-07-12 |
| The Food Effect on PK Characteristics and Safety Profiles of PA-111 (NCT06976489) | Addpharma Inc. | 2025-05-01 |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A (NCT06916130) | Addpharma Inc. | 2025-04-21 |
| A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A (NCT06932705) | Addpharma Inc. | 2025-04-01 |
| The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151' (NCT06902818) | Addpharma Inc. | 2025-03-21 |
| A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284 (NCT06884098) | Addpharma Inc. | 2025-03-10 |
| A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282 (NCT06747936) | Addpharma Inc. | 2025-02-01 |
| A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B (NCT06441630) | Addpharma Inc. | 2024-07-31 |
| Phase III Study to Evaluate the Efficacy and Safety of AD-209 (NCT06348576) | Addpharma Inc. | 2024-05-20 |
| A Study to Evaluate the Efficacy and Safety of AD-224 (NCT06291207) | Addpharma Inc. | 2024-04-15 |
| A Study to Evaluate the Efficacy and Safety of AD-223 (NCT06052748) | Addpharma Inc. | 2024-02-15 |
| A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 (NCT06025773) | Addpharma Inc. | 2023-09-15 |
| A Study to Evaluate the Efficacy and Safety of AD-209 (NCT05631990) | Addpharma Inc. | 2023-04-05 |
| A Study to Assess the Safety and Pharmacokinetics of AD-104-A (NCT05703282) | Addpharma Inc. | 2023-03-13 |
| A Study to Evaluate the Efficacy and Safety of AD-218 (NCT05400317) | Addpharma Inc. | 2022-07-27 |
| A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B (NCT05202405) | Addpharma Inc. | 2022-01-05 |
| A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A (NCT05131997) | Addpharma Inc. | 2021-11-16 |
| A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091 (NCT05128591) | Addpharma Inc. | 2021-11-09 |
| A Study to Compare PK, PD and Safety of the AD-214 and AD-2141 (NCT05062876) | Addpharma Inc. | 2021-11-01 |
| A Study to Evaluate the Efficacy and Safety of AD-208 (NCT04825561) | Addpharma Inc. | 2021-06-09 |
| A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132 (NCT04755985) | Addpharma Inc. | 2021-03-21 |
| A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole (NCT04622358) | Addpharma Inc. | 2020-12-05 |
| Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102 (NCT04600284) | Addpharma Inc. | 2020-11-16 |
| Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 (NCT06448962) | Addpharma Inc. | 2020-10-22 |
| A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole (NCT04494243) | Addpharma Inc. | 2020-08-28 |
| Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112 (NCT04375865) | Addpharma Inc. | 2020-05-30 |
| Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension (NCT04218552) | Addpharma Inc. | 2020-02-25 |
| Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan/Amlodipine (NCT04158076) | Addpharma Inc. | 2020-01-23 |
| To Evaluate the Pharmacokinetics and Safety of AD-208 (NCT04214808) | Addpharma Inc. | 2020-01-03 |
| A Study to Evaluate the Efficacy and Safety of AD-203 (NCT04066530) | Addpharma Inc. | 2019-09-23 |
| Evaluating the Pharmacokinetic Characteristics of AD-102 in Healthy Volunteers (NCT03824171) | Addpharma Inc. | 2019-02-28 |
| Evaluating the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan (NCT03872232) | Addpharma Inc. | 2019-02-26 |
| Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers (NCT03764462) | Addpharma Inc. | 2018-12-14 |
| Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072 (NCT03632668) | Addpharma Inc. | 2018-09-28 |
| Evaluating the Pharmacokinetic Interaction Between AD-2011 and AD-2012 (NCT03586037) | Addpharma Inc. | 2018-06-12 |